carcinoid syndrome


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to carcinoid syndrome: Carcinoid tumor

carcinoid syndrome

[′kärs·ən‚ȯid ′sin‚drōm]
(medicine)
A complex of symptoms arising from the metastasis of a carcinoid tumor to the liver.
References in periodicals archive ?
Serotonin overproduction leads to the carcinoid syndrome, which consists of flushing, diarrhea, bronchial constriction, and carcinoid heart disease (11,12).
These results are exciting from both an efficacy and safety perspective for carcinoid syndrome patients.
We investigated 20 consecutive patients (9 men and 11 women) with histologically confirmed midget carcinoid tumors and a clinical carcinoid syndrome.
Concept behind the TELESTAR Phase 3 Trial - For this double-blind Phase 3 study known as TELESTAR, Lexicon Pharmaceuticals enrolled a total of 135 patients with carcinoid syndrome which was not adequately controlled on the current standard of care, the SSA therapy.
Lexicon is focused on its most advanced drug candidates: telotristat etiprate for carcinoid syndrome, a rare condition that impacts thousands of cancer patients with metastatic neuroendocrine tumors, and sotagliflozin for type 1 diabetes.
The double-blind Phase 3 study known as TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) enrolled 135 patients with carcinoid syndrome which was not adequately controlled on SSA therapy, the current standard of care.
The pivotal Phase 3 trial is comparing telotristat etiprate to placebo on a background of somatostatin analog (SSA) therapy, the current standard of care, in patients whose carcinoid syndrome is not adequately controlled with SSA therapy.
In October 2014, Lexicon completed a collaboration agreement with Ipsen Pharma SAS for the commercialization of telotristat etiprate, with a focus on carcinoid syndrome, in markets outside the United States, Canada and Japan.
Aside from the symptomatic treatment of acromegaly and carcinoid syndrome due to neuroendocrine tumors, BIM 23A760 might potentially also reduce the tumor size, thereby eliminating some of the shortcomings of the treatments currently available.
Telotristat etiprate, Lexicon's most advanced product candidate, met the TELESTAR study's primary endpoint with clinically meaningful reductions in bowel movement frequency in cancer patients whose carcinoid syndrome was not adequately controlled by somatostatin analog (SSA) therapy.
In spite of the presence of hepatic metastases, no carcinoid syndrome occurred.
Neuroendocrine tumors, produce excessive amounts of hormones and include carcinoid syndrome, Zollinger Ellison syndrome, VIPomas, insulinomas gastrinoma, glucaginoma and somatostatinoma, among others.